At the same time, we are working in collaboration with the EMA to finalize and narrow commercial drug product specifications and our commercial drug manufacturing process,” Bluebird Chief Commercial Officer Alison Finger said Friday, according to a recording of the investor call. Bluebird Health has delayed the launch of its Zynteglo gene therapy , despite securing conditional approval from the European Medicines Agency , after it demanded a tightening of product specifications and manufacturing processes . Bluebird has priced Zynteglo , which is for patients with insulin - dependent beta - thalassemia , at € 1.575 ##m ( $ 1.77 m ) in Europe , spread over five years . It plans to enrol its first patients by the end of this year and begin treatment in early September .
Bluebird Health has delayed the launch of its Zynteglo gene therapy , despite securing conditional approval from the European Medicines Agency , after it demanded a tightening of product specifications and manufacturing processes . Bluebird has priced Zynteglo , which is for patients with insulin - dependent beta - thalassemia , at € 1.575 ##m ( $ 1.77 m ) in Europe , spread over five years . It plans to enrol its first patients by the end of this year and begin treatment in early September .